Prevention and management of early esophageal cancer

Current Treatment Options in Oncology

Volumn 5, Issue 5, 2004, Pages 405-416

  Korn, W Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOLEVULINIC ACID; AMINOPHYLLINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; FLUOROURACIL; GLYCERYL TRINITRATE; MITOMYCIN C; NONSTEROID ANTIINFLAMMATORY AGENT; PHOTOFRIN; PROTON PUMP INHIBITOR;

ADENOCARCINOMA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER INFILTRATION; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; EARLY CANCER; EATING HABIT; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC SURGERY; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; ESOPHAGUS RESECTION; ESOPHAGUS SURGERY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL TOXICITY; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; LIFESTYLE; LYMPH NODE METASTASIS; MORBIDITY; NAUSEA; NEUTROPENIA; PHOTODYNAMIC THERAPY; PROGNOSIS; REVIEW; RISK FACTOR; STOMATITIS; SUBMUCOSA;

EID: 8344277936     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0030-6     Document Type: Review

References (85)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
2. Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States Cancer 1998, 83:2049-2053.
3. Parkin DM, Bray F, Ferlay J, et al.: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94 153-156.
4. Lin K, Shen W, Shen Z, et al.: Estimation of the potential for nitrosation and its inhibition in subjects from high- and low-risk areas for esophageal cancer in southern China. Int J Cancer 2003, 107:891-895.
5. Tachibana M, Yoshimura H, Kinugasa S, et al.: Clinicopathological features of superficial squamous cell carcinoma of the esophagus. Am J Surg 1997, 174:49-53.
6. Stein HJ, Brucher BL, Sendler A, et al.: Esophageal cancer: patient evaluation and pretreatment staging. Surg Oncol 2001, 10:103-111.
7. Castellsague X, Munoz N, De Stefani E, et al.: Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. Int J Cancer 1999, 82:657-664.
8. Morita M, Saeki H, Mori M, et al.: Risk factors for esophageal cancer and the multiple occurrence of carcinoma in the upper aerodigestive tract. Surgery 2002, 131(1 Suppl):S1-S6.
9. Castellsague X, Munoz N, De Stefani E, et al.: Influence of mate drinking, hot beverages, and diet on esophageal cancer risk in South America. Int J Cancer 2000, 88:658-664.
10. Risk JM, Mills HS, Garde J, et al.: The tylosis esophageal cancer (TOC) locus; more than just a familial cancer gene. Dis Esophagus 1999, 12:173-176.
11. Brucher BL, Stein HJ, Bartels H, et al.: Achalasia and esophageal cancer: incidence, prevalence, and prognosis. World J Surg 2001, 25:745-749.
12. Shaheen NJ, Crosby MA, Bozymski EM, et al.: Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000, 119:333-338.
13. Lagergren J, Bergstrom P, Lindgren A, et al.: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999, 340:825-831.
14. Cheng KK, Sharp L, McKinney PA, et al.: A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer 2000, 83:127-132.
15. Walther C, Zilling T, Perfekt R, et al.: Increasing prevalence of adenocarcinoma of the oesophagus and gastro-oesophageal junction: a study of the Swedish population between 1970 and 1997. Eur J Surg 2001, 167:748-757.
16. Brown LM, Hoover R, Silverman D, et al.: Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol 2001, 153 114-122.
17. Engel LS, Chow WH, Vaughan TL, et al.: Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003, 95:1404-1413.
18. Sampliner RE: Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002, 97:1888-1895.
19. Corley DA, Levin TR, Habel LA, et al.: Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002, 122:633-640.
20. Stein HJ, Siewert JR: Improved prognosis of resected esophageal cancer. World J Surg 2004, In press.
21. Yoshida S: Endoscopic diagnosis and treatment of early cancer in the alimentary tract. Digestion 1998, 59 502-508.
22. Kelly S, Harris KM, Berry E, et al.: A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut 2001, 49:534-539.
23. Dean DA, Detterbeck FC: Esophageal cancer: staging. In Gastrointestinal Oncology. Edited by Tepper JE, Levin B, Kelsen D, et al. Philadelphia: Lippincott Williams & Wilkins; 2003:251-260.
24. Waxman I: Endosonography in columnar-lined esophagus. Gastroenterol Clin North Am 1997, 26:607-612.
25. May A, Gunter E, Roth F, et al.: Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial Gut 2004, 53:634-640.
26. Terry P, Lagergren J, Hansen H, et al.: Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers Eur J Cancer Prev 2001, 10:365-369.
27. Chainani-Wu N: Diet and oral, pharyngeal, and esophageal cancer. Nutr Cancer 2002, 44:104-126.
28. Blot WJ, Li JY, Taylor PR, et al.: Nutrition intervention trials in linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993, 85:1483-1492.
29. Taylor PR, Qiao YL, Abnet CC, et al.: Prospective study of serum vitamin E levels and esophageal and gastric cancers. J Natl Cancer Inst 2003, 95:1414-1416.
30. Wei WQ, Abnet CC, Qiao YL, et al.: Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. Am J Clin Nutr 2004, 79:80-85.
31. Chow WH, Blot WJ, Vaughan TL, et al.: Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998, 90:150-155.
32. Lagergren J, Bergstrom R, Nyren O: Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999, 130:883-890.
33. Lagergren J, Bergstrom R, Nyren O: No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study. Gut 2000, 47:26-29.
34. Vaughan TL, Davis S, Kristal A, et al.: Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995, 4(2):85-92.
35. Gammon MD, Schoenberg JB, Ahsan H, et al.: Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997, 89:1277-1284.
36. Cheng KK, Duffy SW, Day NE, et al.: Stopping drinking and risk of oesophageal cancer. BMJ 1995, 310 1094-1097.
37. Castellsague X, Munoz N, De Stefani E, et al.: Smoking and drinking cessation and risk of esophageal cancer. Cancer Causes Control 2000, 11:813-818.
38. Lagergren J, Bergstrom R, Adami HO, et al.: Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000, 133:165-175.
39. Zhang F, Altorki NK, Wu YC, et al.: Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology 2001, 121 1391-1399.
40. Sampliner RE: Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998, 93:1028-1032.
41. Canto MI, Setrakian S, Willis J, et al.: Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus. Gastrointest Endosc 2000, 51:560-568.
42. Corley DA, Kerlikowske K, Verma R, et al.: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124:47-56.
43. Morris CD, Armstrong GR, Bigley G, et al.: Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001, 96:990-996.
44. Hur C, Nishioka NS, Gazelle GS: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 2004, 96:316-325.
45. Lerut T, Coosemans W, Van Raemdonck D, et al.: Surgical treatment of Barrett's carcinoma; correlations between morphologic findings and prognosis. J Thorac Cardiovasc Surg 1994, 107:1059-1065; discussion 1065-1066.
46. Holscher AH, Bollschweiler E, Schneider PM, et al.: Early adenocarcinoma in Barrett's oesophagus. Br J Surg 1997, 84:1470-1473.
47. Ando N, Ozawa S, Kitagawa Y, et al.: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000, 232 225-232.
48. Fujita H, Sueyoshi S, Yamana H, et al.: Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy. World J Surg 2001, 25 424-431.
49. Bonavina L, Via A, Incarbone R, et al.: Results of surgical therapy in patients with Barrett's adenocarcinoma. World J Surg 2003, 27:1062-1066.
50. Stein HJ, Feith M, Rahden BA, et al.: Approach to early Barrett's cancer. World J Surg 2003, 27:1040-1046.
51. Lerut T, Coosemans W, Decker G, et al.: Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies. Surg Oncol 2001, 10:113-122.
52. Law S, Kwong DL, Kwok KF, et al.: Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg 2003, 238:339-347; discussion 347-338.
53. Hulscher JB, van Sandick JW, de Boer AG, et al.: Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002, 347:1662-1669.
54. Patti MG, Corvera CU, Glasgow RE, et al.: A hospital's annual rate of esophagectomy influences the operative mortality rate. J Gastrointest Surg 1998, 2:186-192.
55. Swisher SG, Deford L, Merriman KW, et al.: Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg 2000, 119 1126-1132.
56. Nishihira T, Hirayama K, Mori S: A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998, 175 47-51.
57. Altorki N, Kent M, Ferrara C, et al.: Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002, 236:177-183.
58. Orringer MB, Marshall B, Stirling MC: Transhiatal esophagectomy for benign and malignant disease. J Thorac Cardiovasc Surg 1993, 105:265-276; discussion 276-277.
59. Swanstrom LL, Hansen P: Laparoscopic total esophagectomy Arch Surg 1997, 132:943-947; discussion 947-949.
60. Luketich JD, Schauer PR, Christie NA, et al.: Minimally invasive esophagectomy. Ann Thorac Surg 2000, 70 906-911.
61. Nemoto K, Matsumoto Y, Yamakawa M, et al.: Treatment of superficial esophageal cancer by external radiation therapy alone: results of a multi-institutional experience. Int J Radiat Oncol Biol Phys 2000, 46:921-925.
62. Sykes AJ, Burt PA, Slevin NJ, et al.: Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiother Oncol 1998, 48:15-21.
63. Herskovic A, Martz K, al-Sarraf M, et al.: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992, 326 1593-1598.
64. Murakami M, Kuroda Y, Nakajima T, et al.: Comparison between chemoradiation protocol intended for organ preservation and conventional surgery for clinical T1-T2 esophageal carcinoma. Int J Radiat Oncol Biol Phys 1999, 45:277-284.
65. Smith TJ, Ryan LM, Douglass HO Jr, et al.: Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1998, 42:269-276.
66. Muro K, Hamaguchi T, Yamada Y, et al.: Definitive chemoradiotherapy may be standard treatment options in clinical stage I esophageal cancer. In ASCO Gastrointestinal Cancers Symposium; San Francisco: 2004:27.
67. Wong R, Malthaner R: Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus (Cochrane Review) [abstract]. The Cochrane Library, 2001.
68. Minsky B, Pajak T, Ginsberg R, et al.: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20 1151-1153.
69. Waxman I, Saitoh Y, Raju GS, et al.: High-frequency probe EUS-assisted endoscopic mucosal resection: a therapeutic strategy for submucosal tumors of the GI tract. Gastrointest Endosc 2002, 55:44-49.
70. Takeshita K, Tani M, Inoue H, et al.: Endoscopic treatment of early oesophageal or gastric cancer. Gut 1997, 40:123-127.
71. Schlemper RJ, Kato Y, Stolte M: Diagnostic criteria for gastrointestinal carcinomas in Japan and western countries: proposal for a new classification system of gastrointestinal epithelial neoplasia. J Gastroenterol Hepatol 2000, 15(Suppl):G49-G57.
72. May A, Gossner L, Pech O, et al.: Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002, 14 1085-1091.
73. Nijhawan PK, Wang KK: Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointest Endosc 2000, 52:328-332.
74. Overholt BF, Panjehpour M, Halberg DL: Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003, 58 183-188.
75. Wolfsen HC, Woodward TA, Raimondo M: Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma. Mayo Clin Proc 2002, 77:1176-1181.
76. Pacifico RJ, Wang KK, Wongkeesong LM, et al.: Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol 2003, 1:252-257.
77. Weston AP, Sharma P: Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma. Am J Gastroenterol 2002, 97:2998-3006.
78. Sampliner RE: Prevention of adenocarcinoma by reversing Barrett's esophagus with mucosal ablation. World J Surg 2003, 27:1026-1029.
79. Kelsen DP, Ginsberg R, Pajak TF, et al.: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998, 339 1979-1984.
80. Urschel JD, Vasan H, Blewett CJ: A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002, 183:274-279.
81. Arnott SJ, Duncan W, Gignoux M, et al.: Preoperative radiotherapy for esophageal carcinoma (Cochrane Review) [abstract]. The Cochrane Library, 2000:CDO01799.
82. Zieren HU, Muller JM, Jacobi CA, et al.: Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg 1995, 19:444-449.
83. Fok M, Sham JS, Choy D, et al.: Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993, 113:138-147.
84. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
85. Macdonald JS, Smalley S, Benedetti J, et al.: Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: update of the results of Intergroup Study INT-0116 (SWOG 9008). Gastrointest Cancers Symp 2004, 6.